NCT02812342View on ClinicalTrials.gov

Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

July 31, 2018

Study Completion Date

December 31, 2018

Conditions
Alopecia AreataAlopecia TotalisAlopecia Universalis
Interventions
DRUG

Tofacitinib ointment

Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.

Trial Locations (1)

06510

Yale-New Haven Hospital, New Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT02812342 - Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants | Biotech Hunter | Biotech Hunter